Gardasil Articles
Gardasil submitted for WHO prequalification
23 July 2007
Rotateq/Gardasil on all US VFC programs
23 July 2007
UK's ABPI "admonishes" Bayer, GSK and Roche
16 July 2007
France to begin Gardasil reimbursement
16 July 2007
Gardasil shows long-lasting efficacy
9 July 2007
California officials push for total vacc powers
9 July 2007
FDA opts for standard review of Cervarix
11 June 2007
Activist group releases Gardasil AE data
4 June 2007
Sanofi Pasteur MSD's Gardasil shows strong efficacy in FUTURE trials but questions remain
21 May 2007
Sweden adds Gardasil to reimbursement list
21 May 2007
Australian R&D tax breaks announced
14 May 2007
Merck & Co's 1st-qtr income climbs 12%
30 April 2007
Rise in vaccine costs "put children at risk"
23 April 2007
Germany introduces HPV vacc, Italy to follow
9 April 2007
GSK submits Cervarix BLA to US FDA
9 April 2007
UK heath panel delays Gardasil
19 March 2007
Stock Commentary - Europe - week to March 5, 2007
12 March 2007
Placebo groups to be switched to Gardasil
5 March 2007
Stock Commentary - New York week to Feb 26, 2007
5 March 2007
Merck & Co suspends lobbying to make Gardasil compulsory ahead of report on its side effects
26 February 2007
World vaccine market to exceed $15 billion in 2012
19 February 2007
Merck & Co's 4th-qtr income plunges 58%
5 February 2007
Gardasil registration in Italy in "final phase"
29 January 2007
France's Afssaps to review four drugs
29 January 2007
Gardasil could slash cervical cancer 78%
29 January 2007
GSK's initiates trial of Cervarix vs Merck's Gardasil
22 January 2007
Call for rapid worldwide access to new cervical cancer vaccines
22 December 2006
Merck & Co's reaffirms cautious 2006 EPS
18 December 2006
USA's CDC adds Merck & Co's Gardasil to its VFC contract
6 November 2006
MedImmune's 3rd-qtr loss down 13% $55.8M
6 November 2006
Sanofi Pasteur MSD's Gardasil beating GSK's Cervarix in race to dominate HPV vacc market
30 October 2006
Merck & Co's 3rd-qtr income down 38% to $904.6 million on flat sales and higher costs
30 October 2006
Merck & Co delays 2007 filing of MK-524B on formulation issue, pre-2009 launch unlikely
9 October 2006
Sanofi MSD's Gardasil could cross-protect
11 September 2006
Gardasil receives positive CHMP recommendation
7 August 2006
Blue Shield California covers Merck & Co's Gardasil
26 July 2006
Stock Commentary - New York week to July 3, 2006
10 July 2006
US FDA approves Merck & Co's Gardasil: First cervical cancer vacc, potential blockbuster
19 June 2006
GSK's sees strong efficacy across wide age group
12 June 2006
Gardasil gets FDA nod for cervical cancer
29 May 2006
Merck & Co's Rotateq gets FDA OK
13 February 2006
Merck & Co's Gardasil BLA "on track"
13 February 2006
US FDA accepts Merck's Gardasil BLA
13 February 2006
Sanofi Pasteur MSD to submit MAA to EMEA for Gardasil
19 December 2005
Merck & Co files BLA for Gardasil with US FDA
12 December 2005
Gardisil: higher efficacy in young adolescents
30 May 2005
- Drug prices to plunge as Indian government announces plans to regulate rates of 652 medicines
- Elan makes "transformational" acquisitions and a divestment
- HIV vaccines: small biotech and government-funded organizations will step in where Big Pharma has fallen short, says analyst
- Is failure to adopt business process management putting the pharma industry at risk?
- Greek research-based drugmaker group AIFD challenges generics assumptions in Draft Patent Law
